We are live on ! Find out more
EAM

Exome Asset Management Portfolio holdings

AUM $193M
1-Year Est. Return 208.51%
This Fund
S&P 500
This Quarter Est. Return
+9.78%
1 Year Est. Return
+208.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$133M
AUM Growth
-$14.8M
Cap. Flow
-$12.1M
Cap. Flow %
-9.06%
Top 10 Hldgs %
36.98%
Holding
83
New
24
Increased
11
Reduced
18
Closed
24

Top Buys

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$5.46M
2
ARVN icon
Arvinas
ARVN
+$5.31M
3
HUM icon
Humana
HUM
+$4.85M
4
SLNO
Soleno Therapeutics
SLNO
+$4M
5
RLAY icon
Relay Therapeutics
RLAY
+$3.64M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$6.55M
2
TGTX icon
TG Therapeutics
TGTX
+$4.86M
3
ALGN icon
Align Technology
ALGN
+$4.76M
4
CI icon
Cigna
CI
+$4.23M
5
BNTX icon
BioNTech
BNTX
+$4.1M

Sector Composition

Rank Sector Weight
1 Healthcare 98.45%
2 Financials 0.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STAA icon
76
STAAR Surgical
STAA
$1.21B
– –
-40,800
Closed -$1.52M
SWTX
77
DELISTED
SpringWorks Therapeutics
SWTX
– –
-100,700
Closed -$3.23M
TGTX icon
78
TG Therapeutics
TGTX
$7.96B
– –
-207,627
Closed -$4.86M
VRDN icon
79
Viridian Therapeutics
VRDN
$2.09B
– –
-174,400
Closed -$3.97M
SYRS
80
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-298,575
Closed -$642K
RVNC
81
DELISTED
Revance Therapeutics, Inc.
RVNC
– –
-347,600
Closed -$1.8M
PROC
82
DELISTED
Procaps Group, S.A. Ordinary Shares
PROC
– –
-126,901
Closed -$280K
1 2 3
4

Similar funds

WWC
Waypoint Wealth Counsel Atlanta, Georgia $193M AUM 30.17% 1-Year Est. Return
JHA
Jackson Hill Advisors Houston, Texas $193M AUM 4.94% 1-Year Est. Return
TDWM
Topel & Distasi Wealth Management Berkeley, California $193M AUM 12.07% 1-Year Est. Return
DF
Downshift Financial Boulder, Colorado $193M AUM
SCM
Sandler Capital Management New York $193M AUM 77.14% 1-Year Est. Return
PA
Promethium Advisors Bethesda, Maryland $193M AUM 23.69% 1-Year Est. Return
SCPM
Sea Cliff Partners Management San Francisco, California $194M AUM 8.22% 1-Year Est. Return
CA
Carson Advisory Athens, Georgia $193M AUM 14.52% 1-Year Est. Return

Exome Asset Management's Q4 2024 Portfolio in Review

As of Q4 2024, Exome Asset Management held 83 positions worth $133M, down 10% from $148M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Exome Asset Management withdrew a net $12.1M in Q4 2024, closing 24 positions and reducing 18 holdings. Its most notable exit was Ascendis Pharma A/S, an estimated $6.55M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Financials.

Against the trend, Exome Asset Management opened a new position in Syndax Pharmaceuticals worth $4.22M.

  • Exome Asset Management's largest Q4 2024 buy was Syndax Pharmaceuticals: 318,900 shares worth $4.22M.
  • Exome Asset Management added most to Relay Therapeutics in Q4 2024, an estimated $3.64M increase.
  • Exome Asset Management's biggest Q4 2024 reduction was Mersana Therapeutics, cutting an estimated $2.08M.
  • Exome Asset Management fully exited Ascendis Pharma A/S in Q4 2024, selling an estimated $6.55M.
  • Exome Asset Management's ten largest holdings make up 37% of its $133M portfolio in Q4 2024.
  • Exome Asset Management opened 24 new positions and closed 24 in Q4 2024.
  • Exome Asset Management's portfolio value fell 10% quarter-over-quarter to $133M.

Based on Exome Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.